GlaxoSmithKline Stock Price, News & Analysis (NYSE:GSK)

$37.92 0.42 (1.12 %)
(As of 01/16/2018 04:00 PM ET)
Previous Close$37.92
Today's Range$37.69 - $38.12
52-Week Range$34.52 - $44.53
Volume7.44 million shs
Average Volume5.40 million shs
Market Capitalization$93.53 billion
P/E Ratio28.95
Dividend Yield5.45%
Beta0.97

About GlaxoSmithKline (NYSE:GSK)

GlaxoSmithKline logoGlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines, vaccines and consumer healthcare products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. The Consumer Healthcare business develops and markets products in Wellness, Oral health, Nutrition and Skin health categories. Its product portfolio includes Adartrel, Bexsero, Daraprim and Quinvaxem. Its brands include Panadol, abreva, polident and physiogel.

Receive GSK News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorHealthcare
SymbolNYSE:GSK
CUSIPN/A
Phone+44-20-80475000

Debt

Debt-to-Equity Ratio2.96%
Current Ratio0.64%
Quick Ratio0.44%

Price-To-Earnings

Trailing P/E Ratio28.9465648854962
Forward P/E Ratio13.08
P/E Growth2.15

Sales & Book Value

Annual Sales$37.82 billion
Price / Sales2.49
Cash Flow$4.04 per share
Price / Cash9.38
Book Value$2.74 per share
Price / Book13.84

Profitability

Trailing EPS$1.31
Net Income$1.24 billion
Net Margins7.79%
Return on Equity115.30%
Return on Assets9.69%

Miscellaneous

Employees99,827
Outstanding Shares2,478,970,000

GlaxoSmithKline (NYSE:GSK) Frequently Asked Questions

What is GlaxoSmithKline's stock symbol?

GlaxoSmithKline trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

How often does GlaxoSmithKline pay dividends? What is the dividend yield for GlaxoSmithKline?

GlaxoSmithKline announced a quarterly dividend on Thursday, October 26th. Stockholders of record on Friday, November 10th will be given a dividend of $0.5037 per share on Thursday, January 11th. This represents a $2.01 annualized dividend and a dividend yield of 5.31%. The ex-dividend date is Thursday, November 9th. This is a boost from GlaxoSmithKline's previous quarterly dividend of $0.49. View GlaxoSmithKline's Dividend History.

How were GlaxoSmithKline's earnings last quarter?

GlaxoSmithKline plc (NYSE:GSK) posted its quarterly earnings results on Wednesday, October, 25th. The pharmaceutical company reported $0.85 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.84 by $0.01. GlaxoSmithKline had a net margin of 7.79% and a return on equity of 115.30%. View GlaxoSmithKline's Earnings History.

When will GlaxoSmithKline make its next earnings announcement?

GlaxoSmithKline is scheduled to release their next quarterly earnings announcement on Wednesday, February, 14th 2018. View Earnings Estimates for GlaxoSmithKline.

Where is GlaxoSmithKline's stock going? Where will GlaxoSmithKline's stock price be in 2018?

15 brokers have issued 1-year target prices for GlaxoSmithKline's shares. Their forecasts range from $37.00 to $40.00. On average, they expect GlaxoSmithKline's stock price to reach $38.33 in the next year. View Analyst Ratings for GlaxoSmithKline.

Are investors shorting GlaxoSmithKline?

GlaxoSmithKline saw a drop in short interest during the month of November. As of November 30th, there was short interest totalling 10,397,225 shares, a drop of 22.3% from the November 15th total of 13,387,745 shares. Based on an average trading volume of 4,254,511 shares, the days-to-cover ratio is presently 2.4 days. Currently, 0.4% of the company's shares are short sold.

Who are some of GlaxoSmithKline's key competitors?

Who are GlaxoSmithKline's key executives?

GlaxoSmithKline's management team includes the folowing people:

  • Emma Walmsley, Chief Executive Officer, Executive Director (Age 47)
  • Simon Dingemans, Chief Financial Officer, Executive Director (Age 53)
  • Patrick Vallance, President - R&D, Executive Director (Age 56)
  • Roger Connor, President - Global Manufacturing & Supply
  • Luc Debruyne, President - Global Vaccines
  • Abbas Hussain, President - Global Pharmaceuticals
  • Shah Abbas Hussain, President - Global Pharmaceuticals
  • Brian McNamara, Chief Executive Officer - GSK Consumer Healthcare (Age 50)
  • Luke Miels, President - Global Pharmaceuticals
  • Daniel E. Troy, Senior Vice President, General Counsel

Who owns GlaxoSmithKline stock?

GlaxoSmithKline's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Confluence Investment Management LLC (0.07%), Bank of Montreal Can (0.01%), Fulton Bank N.A. (0.00%), Greylin Investment Mangement Inc. (0.00%), BLB&B Advisors LLC (0.00%) and Gofen & Glossberg LLC IL (0.00%). View Institutional Ownership Trends for GlaxoSmithKline.

Who sold GlaxoSmithKline stock? Who is selling GlaxoSmithKline stock?

GlaxoSmithKline's stock was sold by a variety of institutional investors in the last quarter, including Confluence Investment Management LLC, Bank of Montreal Can, Beacon Financial Group, Greylin Investment Mangement Inc., Bonness Enterprises Inc., BLB&B Advisors LLC, First PREMIER Bank and Gofen & Glossberg LLC IL. View Insider Buying and Selling for GlaxoSmithKline.

Who bought GlaxoSmithKline stock? Who is buying GlaxoSmithKline stock?

GlaxoSmithKline's stock was purchased by a variety of institutional investors in the last quarter, including KCS Wealth Advisory, E&G Advisors LP, Bogart Wealth LLC and Atria Investments LLC. View Insider Buying and Selling for GlaxoSmithKline.

How do I buy GlaxoSmithKline stock?

Shares of GlaxoSmithKline can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GlaxoSmithKline's stock price today?

One share of GlaxoSmithKline stock can currently be purchased for approximately $37.92.

How big of a company is GlaxoSmithKline?

GlaxoSmithKline has a market capitalization of $93.53 billion and generates $37.82 billion in revenue each year. The pharmaceutical company earns $1.24 billion in net income (profit) each year or $1.31 on an earnings per share basis. GlaxoSmithKline employs 99,827 workers across the globe.

How can I contact GlaxoSmithKline?

GlaxoSmithKline's mailing address is 980 Great West Road, BRENTFORD, TW8 9GS, United Kingdom. The pharmaceutical company can be reached via phone at +44-20-80475000 or via email at [email protected]


MarketBeat Community Rating for GlaxoSmithKline (GSK)

Community Ranking:  1.7 out of 5 (star)
Outperform Votes:  349 (Vote Outperform)
Underperform Votes:  674 (Vote Underperform)
Total Votes:  1,023
MarketBeat's community ratings are surveys of what our community members think about GlaxoSmithKline and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

GlaxoSmithKline (NYSE:GSK) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.202.192.332.47
Ratings Breakdown: 2 Sell Rating(s)
8 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
9 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
6 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
7 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $38.33$38.33$43.50$45.67
Price Target Upside: 2.22% upside8.99% upside6.54% upside7.40% upside

GlaxoSmithKline (NYSE:GSK) Consensus Price Target History

Price Target History for GlaxoSmithKline (NYSE:GSK)

GlaxoSmithKline (NYSE:GSK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/16/2018BarclaysUpgradeEqual Weight -> OverweightLowView Rating Details
1/11/2018JPMorgan Chase & Co.Reiterated RatingNeutralLowView Rating Details
12/11/2017CowenSet Price TargetHold$38.00LowView Rating Details
11/30/2017ArgusLower Price TargetBuy$40.00LowView Rating Details
11/6/2017InvestecDowngradeBuy -> HoldN/AView Rating Details
10/26/2017Bank of AmericaDowngradeBuy -> NeutralN/AView Rating Details
9/8/2017Morgan StanleyDowngradeEqual Weight -> UnderweightLowView Rating Details
7/27/2017CitigroupReiterated RatingNeutralLowView Rating Details
5/26/2017Berenberg BankUpgradeHold -> BuyLowView Rating Details
4/6/2017BNP ParibasLower Price Target$37.00LowView Rating Details
4/5/2017Exane BNP ParibasUpgradeUnderperform -> NeutralLowView Rating Details
3/9/2017Liberum CapitalInitiated CoverageBuy -> BuyLowView Rating Details
3/9/2017Kepler Capital MarketsInitiated CoverageReduce -> ReduceLowView Rating Details
2/19/2017Jefferies GroupReiterated RatingBuyN/AView Rating Details
2/9/2017Deutsche BankReiterated RatingNeutralN/AView Rating Details
12/27/2016Goldman Sachs GroupReiterated RatingBuyN/AView Rating Details
10/26/2016Beaufort SecuritiesReiterated RatingBuyN/AView Rating Details
9/23/2016Piper Jaffray CompaniesInitiated CoverageOverweightN/AView Rating Details
8/17/2016Shore CapitalReiterated RatingHoldN/AView Rating Details
5/5/2016Oddo SecuritiesUpgradeReduce -> BuyN/AView Rating Details
2/26/2016Cantor FitzgeraldInitiated CoverageHoldN/AView Rating Details
2/4/2016Sanford C. BernsteinBoost Price TargetMarket Perform$43.00 -> $45.00N/AView Rating Details
1/27/2016Bryan, Garnier & CoUpgradeNeutral -> BuyN/AView Rating Details
(Data available from 1/16/2016 forward)

Earnings

GlaxoSmithKline (NYSE:GSK) Earnings History and Estimates Chart

Earnings by Quarter for GlaxoSmithKline (NYSE:GSK)

GlaxoSmithKline (NYSE GSK) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/14/2018        
10/25/2017Q3 2017$0.84$0.85ViewN/AView Earnings Details
7/26/20176/30/2017$0.68$0.70$9.52 billion$9.36 billionViewN/AView Earnings Details
4/26/20173/31/2017$0.62$0.62$9.09 billion$9.23 billionViewN/AView Earnings Details
2/8/201712/31/2016$0.57$0.65$9.21 billion$9.43 billionViewListenView Earnings Details
10/26/2016Q316$0.77$0.83$8.92 billion$9.90 billionViewListenView Earnings Details
7/27/2016Q2 2016$0.55$0.70ViewN/AView Earnings Details
4/27/2016Q1 2016$0.60$0.57ViewN/AView Earnings Details
2/3/2016Q4 2015$0.52$0.55ViewN/AView Earnings Details
10/28/2015Q3$0.60$0.71$6.07 billion$6.13 billionViewN/AView Earnings Details
7/29/2015Q215$0.50$0.53$9.14 billion$9.02 billionViewN/AView Earnings Details
5/6/2015Q115$0.55$0.48$8.55 billion$8.51 billionViewN/AView Earnings Details
2/4/2015Q414$0.86$0.82$6.14 billion$6.19 billionViewN/AView Earnings Details
10/22/2014Q314$0.79$0.90$9.76 billion$9.12 billionViewListenView Earnings Details
7/23/2014Q114$0.71$0.65$10.13 billion$9.47 billionViewN/AView Earnings Details
4/30/2014Q413$0.72$0.70$10.36 billion$9.44 billionViewN/AView Earnings Details
2/5/2014Q4$0.30$0.30$6.84 billion$6.91 billionViewN/AView Earnings Details
10/23/2013Q313$0.31$10.31 billion$10.09 billionViewN/AView Earnings Details
7/24/2013$0.26$0.26$6.62 billionViewN/AView Earnings Details
4/25/2013Q1 2013$0.77$0.82ViewN/AView Earnings Details
2/6/2013Q4 2012$0.96$1.04ViewN/AView Earnings Details
10/31/2012Q3 2012$0.89$0.85ViewN/AView Earnings Details
7/25/2012Q2 2012$0.84$0.82ViewN/AView Earnings Details
4/25/2012$0.29$0.27ViewN/AView Earnings Details
2/7/2012$0.30$0.28ViewN/AView Earnings Details
10/26/2011Q3 2011$0.90$0.89ViewN/AView Earnings Details
7/26/2011Q2 2011$0.77$0.81ViewN/AView Earnings Details
4/27/2011Q1 2011$1.00$1.02ViewN/AView Earnings Details
2/3/2011Q4 2010$0.88$0.91ViewN/AView Earnings Details
7/21/2010Q2 2010$0.88$0.10ViewN/AView Earnings Details
4/28/2010Q1 2010$0.86$0.93ViewN/AView Earnings Details
2/7/2010Q4 2009$1.12$1.14ViewN/AView Earnings Details
11/2/2009Q3 2009$0.96$0.93ViewN/AView Earnings Details
7/22/2009Q2 2009$0.86$1.02ViewN/AView Earnings Details
2/5/2009Q4 2008$0.80$0.81ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

GlaxoSmithKline (NYSE:GSK) Earnings Estimates

Current Year EPS Consensus Estimate: $2.9 EPS
Next Year EPS Consensus Estimate: $2.8 EPS

Dividends

GlaxoSmithKline (NYSE:GSK) Dividend Information

Most Recent Dividend:1/11/2018
Annual Dividend:$2.04
Dividend Yield:5.38%
Dividend Growth:-8.90% (3 Year Average)
Payout Ratio:155.73% (Trailing 12 Months of Earnings)
70.34% (Based on This Year's Estimates)
72.86% (Based on Next Year's Estimates)
Frequency:Quarterly Dividend
Dividend Payments by Quarter for GlaxoSmithKline (NYSE:GSK)

GlaxoSmithKline (NYSE:GSK) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/26/2017quarterly$0.505.51%11/9/201711/10/20171/11/2018
7/26/2017Quarterly$0.494.88%8/9/20178/11/201710/12/2017
4/26/2017quarterly$0.484.79%5/10/20175/12/20177/13/2017
2/8/2017quarterly$0.575.76%2/22/20172/24/20174/13/2017
10/26/2016$0.4611/2/201611/4/20161/12/2017
7/27/2016$0.498/10/20168/12/201610/13/2016
4/28/2016$0.555/11/20165/13/20167/14/2016
10/28/2015$0.5811/10/201511/13/20151/14/2016
5/7/2015quarterly$0.585.22%5/13/20155/15/20157/9/2015
2/5/2015quarterly$0.706.05%2/18/20152/20/20154/9/2015
10/23/2014quarterly$0.615.41%11/5/201411/7/20141/8/2015
7/24/2014quarterly$0.655.18%8/6/20148/8/201410/2/2014
5/1/2014quarterly$0.644.62%5/14/20145/16/20147/10/2014
2/5/2014$0.752/19/20142/21/20144/10/2014
2/6/2014quarterly$0.755.73%2/19/20142/21/20144/10/2014
10/24/2013quarterly$0.624.76%11/13/201311/15/20131/9/2014
7/25/2013quarterly$0.554.27%8/7/20138/9/201310/3/2013
4/25/2013quarterly$0.554.25%5/8/20135/10/20137/11/2013
2/7/2013quarterly$0.070.61%2/20/20132/22/20134/11/2013
(Data available from 1/1/2013 forward)

Insider Trades

GlaxoSmithKline (NYSE GSK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.00%
Institutional Ownership Percentage: 9.80%
Insider Trades by Quarter for GlaxoSmithKline (NYSE:GSK)
Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

GlaxoSmithKline (NYSE GSK) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/6/2017Plc GlaxosmithklineMajor ShareholderBuy428,571$14.00$5,999,994.00View SEC Filing  
10/24/2016Plc GlaxosmithklineMajor ShareholderBuy66,500$14.00$931,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

GlaxoSmithKline (NYSE GSK) News Headlines

Source:
DateHeadline
What does GlaxoSmithKline plc’s (LON:GSK) Balance Sheet Tell Us Abouts Its Future?What does GlaxoSmithKline plc’s (LON:GSK) Balance Sheet Tell Us Abouts Its Future?
finance.yahoo.com - January 16 at 5:02 PM
GlaxoSmithKline (GSK) Raised to Overweight at BarclaysGlaxoSmithKline (GSK) Raised to Overweight at Barclays
www.americanbankingnews.com - January 16 at 12:42 PM
GlaxoSmithKlines (GSK) "Buy" Rating Reiterated at UBS GroupGlaxoSmithKline's (GSK) "Buy" Rating Reiterated at UBS Group
www.americanbankingnews.com - January 15 at 11:02 AM
What Are Insys Therapeutics’ Top Priorities?What Are Insys Therapeutics’ Top Priorities?
finance.yahoo.com - January 15 at 9:43 AM
AstraZeneca's Asthma Drug Benralizumab Gets Approval in EUAstraZeneca's Asthma Drug Benralizumab Gets Approval in EU
finance.yahoo.com - January 11 at 10:08 AM
GlaxoSmithKline (GSK) Earns Neutral Rating from JPMorgan Chase & Co.GlaxoSmithKline (GSK) Earns Neutral Rating from JPMorgan Chase & Co.
www.americanbankingnews.com - January 11 at 6:06 AM
Key Risks Facing Mylan in January 2018Key Risks Facing Mylan in January 2018
finance.yahoo.com - January 10 at 9:54 AM
GSK's Redfern Says Pharma Remains Number One PriorityGSK's Redfern Says Pharma Remains Number One Priority
finance.yahoo.com - January 9 at 9:48 AM
Glaxo CEO Replaced 50 Top Managers in Shakeup to Spur GrowthGlaxo CEO Replaced 50 Top Managers in Shakeup to Spur Growth
finance.yahoo.com - January 9 at 9:48 AM
GSK CEO: Our top priority is to invest in growth in our c...GSK CEO: Our top priority is to invest in growth in our c...
finance.yahoo.com - January 8 at 5:09 PM
GlaxoSmithKline plc (GSK) Expected to Announce Quarterly Sales of $9.89 BillionGlaxoSmithKline plc (GSK) Expected to Announce Quarterly Sales of $9.89 Billion
www.americanbankingnews.com - January 8 at 10:30 AM
GlaxoSmithKline (GSK) Lowered to Hold at Zacks Investment ResearchGlaxoSmithKline (GSK) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - January 7 at 8:50 PM
 Brokerages Anticipate GlaxoSmithKline plc (GSK) Will Post Earnings of $0.65 Per Share Brokerages Anticipate GlaxoSmithKline plc (GSK) Will Post Earnings of $0.65 Per Share
www.americanbankingnews.com - January 6 at 3:36 PM
GlaxoSmithKline plc (GSK) Given Average Recommendation of "Hold" by BrokeragesGlaxoSmithKline plc (GSK) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - January 5 at 5:50 PM
How Did Novo Nordisk’s Victoza and Saxendra Perform in 3Q17?How Did Novo Nordisk’s Victoza and Saxendra Perform in 3Q17?
finance.yahoo.com - January 5 at 9:56 AM
5 Reasons to Invest in Novo Nordisk (NVO) Stock Right Now5 Reasons to Invest in Novo Nordisk (NVO) Stock Right Now
finance.yahoo.com - January 3 at 9:04 AM
GlaxoSmithKline (GSK) Raised to "Buy" at Zacks Investment ResearchGlaxoSmithKline (GSK) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - January 2 at 12:44 PM
ValuEngine Lowers GlaxoSmithKline (GSK) to HoldValuEngine Lowers GlaxoSmithKline (GSK) to Hold
www.americanbankingnews.com - January 2 at 12:04 AM
GlaxoSmithKline Is a Massive BargainGlaxoSmithKline Is a Massive Bargain
finance.yahoo.com - December 30 at 4:55 PM
Top 5 Dividend Stocks in the FTSE for 2018Top 5 Dividend Stocks in the FTSE for 2018
finance.yahoo.com - December 28 at 3:42 PM
Should You Sell GlaxoSmithKline plc (LON:GSK) At This PE Ratio?Should You Sell GlaxoSmithKline plc (LON:GSK) At This PE Ratio?
finance.yahoo.com - December 25 at 6:46 PM
Aceto (ACET) and GlaxoSmithKline (GSK) Critical ReviewAceto (ACET) and GlaxoSmithKline (GSK) Critical Review
www.americanbankingnews.com - December 23 at 7:24 PM
GSK's history spans three centuries and started in three ...GSK's history spans three centuries and started in three ...
finance.yahoo.com - December 19 at 5:03 PM
ETFs with exposure to GlaxoSmithKline Plc : December 19, 2017ETFs with exposure to GlaxoSmithKline Plc : December 19, 2017
finance.yahoo.com - December 19 at 5:03 PM
TOP NEWS: GlaxoSmithKline Increases Stake In Saudi Arabia VentureTOP NEWS: GlaxoSmithKline Increases Stake In Saudi Arabia Venture
www.morningstar.co.uk - December 18 at 5:02 PM
Short Interest in GlaxoSmithKline plc (GSK) Drops By 22.3%Short Interest in GlaxoSmithKline plc (GSK) Drops By 22.3%
www.americanbankingnews.com - December 18 at 5:12 AM
Head to Head Comparison: GlaxoSmithKline (GSK) & Marinus Pharmaceuticals (MRNS)Head to Head Comparison: GlaxoSmithKline (GSK) & Marinus Pharmaceuticals (MRNS)
www.americanbankingnews.com - December 17 at 5:32 AM
GSK Gets FDA Approval For Nucala For Treatment Of EGPA For AdultsGSK Gets FDA Approval For Nucala For Treatment Of EGPA For Adults
www.nasdaq.com - December 13 at 5:14 PM
GSK achieves approval for Nucala (mepolizumab) for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) for adults in the USGSK achieves approval for Nucala (mepolizumab) for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) for adults in the US
finance.yahoo.com - December 12 at 5:27 PM
GlaxoSmithKline plc (GSK) Receives Consensus Recommendation of "Hold" from AnalystsGlaxoSmithKline plc (GSK) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - December 11 at 7:42 PM
Cowen Reiterates "$38.00" Price Target for GlaxoSmithKline (GSK)Cowen Reiterates "$38.00" Price Target for GlaxoSmithKline (GSK)
www.americanbankingnews.com - December 11 at 3:40 PM
GlaxoSmithKline’s (GSK) Upgraded to HoldGlaxoSmithKline’s (GSK) Upgraded to Hold
investorplace.com - December 8 at 4:58 PM
ETFs with exposure to GlaxoSmithKline Plc : December 8, 2017ETFs with exposure to GlaxoSmithKline Plc : December 8, 2017
finance.yahoo.com - December 8 at 4:58 PM
GlaxoSmithKline’s (GSK) Upgraded to HoldGlaxoSmithKline’s (GSK) Upgraded to Hold
investorplace.com - December 8 at 12:31 PM
Interesting GSK Put And Call Options For January 2018Interesting GSK Put And Call Options For January 2018
www.nasdaq.com - December 7 at 5:27 PM
GlaxoSmithKlines Rockville chief lays out priorities for 2018GlaxoSmithKline's Rockville chief lays out priorities for 2018
finance.yahoo.com - December 7 at 5:27 PM
GlaxoSmithKline’s Consumer Healthcare Business in 3Q17GlaxoSmithKline’s Consumer Healthcare Business in 3Q17
finance.yahoo.com - December 6 at 9:58 AM
GlaxoSmithKline’s Global Pharmaceuticals Business in 3Q17GlaxoSmithKline’s Global Pharmaceuticals Business in 3Q17
finance.yahoo.com - December 5 at 5:00 PM
GlaxoSmithKline and the Dividend MirageGlaxoSmithKline and the Dividend Mirage
finance.yahoo.com - December 5 at 5:00 PM
Glaxos Karenann Terrell Enlists AI in Understanding HIV PatientsGlaxo's Karenann Terrell Enlists AI in Understanding HIV Patients
finance.yahoo.com - December 5 at 5:00 PM
$9.89 Billion in Sales Expected for GlaxoSmithKline plc (GSK) This Quarter$9.89 Billion in Sales Expected for GlaxoSmithKline plc (GSK) This Quarter
www.americanbankingnews.com - December 5 at 9:06 AM
GlaxoSmithKline’s Business Segments in 3Q17GlaxoSmithKline’s Business Segments in 3Q17
finance.yahoo.com - December 4 at 5:03 PM
Is a Dividend Cut Coming From GlaxoSmithKline plc? - Motley FoolIs a Dividend Cut Coming From GlaxoSmithKline plc? - Motley Fool
www.fool.com - December 3 at 5:03 PM
GlaxoSmithKline plc (GSK) Expected to Post Earnings of $0.64 Per ShareGlaxoSmithKline plc (GSK) Expected to Post Earnings of $0.64 Per Share
www.americanbankingnews.com - December 3 at 9:26 AM
GlaxoSmithKline Begins Phase III Study On Injection To Prevent HIVGlaxoSmithKline Begins Phase III Study On Injection To Prevent HIV
www.benzinga.com - December 2 at 9:32 AM
COMM 2015-LC19 Mortgage Trust -- Moodys Affirms Six Classes of COMM 2015-LC19COMM 2015-LC19 Mortgage Trust -- Moody's Affirms Six Classes of COMM 2015-LC19
finance.yahoo.com - November 30 at 5:01 PM
GSK starts big African study of injectable drug to prevent HIVGSK starts big African study of injectable drug to prevent HIV
finance.yahoo.com - November 30 at 10:17 AM
GlaxoSmithKline (GSK) Price Target Cut to $40.00 by Analysts at ArgusGlaxoSmithKline (GSK) Price Target Cut to $40.00 by Analysts at Argus
www.americanbankingnews.com - November 30 at 8:58 AM
Better Buy: GlaxoSmithKline plc vs. PfizerBetter Buy: GlaxoSmithKline plc vs. Pfizer
www.fool.com - November 30 at 7:27 AM
GlaxoSmithKline plc (GSK) Upgraded at UBS AGGlaxoSmithKline plc (GSK) Upgraded at UBS AG
www.americanbankingnews.com - November 27 at 6:50 PM

SEC Filings

GlaxoSmithKline (NYSE:GSK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

GlaxoSmithKline (NYSE:GSK) Income Statement, Balance Sheet and Cash Flow Statement

Chart

GlaxoSmithKline (NYSE GSK) Stock Chart for Tuesday, January, 16, 2018

Loading chart…

This page was last updated on 1/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.